Transformation of adenocarcinoma into small cell lung cancer as one of the mechanisms of acquired resistance to anti-EGFR tyrosine kinase inhibitors
DOI:
https://doi.org/10.14739/2310-1237.2024.1.298373Keywords:
lung adenocarcinoma, small cell lung cancer, cell transdifferentiation, tyrosine kinase inhibitors, resistanceAbstract
Transformation of adenocarcinoma into small cell lung cancer (SCLC) is a rare and unique biological property of a cancer cell that is responsible for the mechanism of acquired resistance to EGFR tyrosine kinase inhibitors.
There are very few clinical observations of phenotypic cellular transformation during metastatic progression of lung cancer in the literature.
The aim of the work is to demonstrate clinical observation of phenotypic transformation of metastatic EGFR-mutated adenocarcinoma into small cell lung cancer with neuroendocrine differentiation during therapy with tyrosine kinase inhibitors.
Case report. Due to the rarity of this biological phenomenon, we describe our own observation of the transformation of EGFR-mutated metastatic adenocarcinoma into DCLC with neuroendocrine differentiation, which occurred in a 42-year-old woman during treatment with gefitinib.
Conclusions. Transformation and changes in cell phenotype during tyrosine kinase inhibitor therapy were the cause of resistance and failure of further treatment with osimertinib in the second line. It was concluded that it is necessary to consider this mechanism of resistance in clinical practice and to perform repeat biopsies during metastatic progression in patients with EGFR-mutated lung adenocarcinoma.
References
Zeng C, Qiu G, Xie X, Liu T, Chen Z, Zhang X, et al. Combined small cell lung cancer: current progress and unmet needs. Am J Cancer Res. 2023;13(9):3864-74.
Ullah A, Saeed O, Karki NR, Goodbee M, Yasinzai AQK, Waheed A, et al. Clinicopathological and Treatment Patterns of Combined Small-Cell Lung Carcinoma with Future Insight to Treatment: A Population-Based Study. J Clin Med. 2023;12(3):991. doi: https://doi.org/10.3390/jcm12030991
He J, Xu S, Pan H, Li S, He J. Treatments for combined small cell lung cancer patients. Transl Lung Cancer Res. 2020;9(5):1785-94. doi: https://doi.org/10.21037/tlcr-20-437
Nishimatsu K, Minami S, Ihara S, Yasuoka H. Transformation From Adenocarcinoma to Pleomorphic Carcinoma as an Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. J Med Cases. 2021;12(8):310-4. doi: https://doi.org/10.14740/jmc3710
Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nat Rev Dis Primers. 2021;7(1):3. doi: https://doi.org/10.1038/s41572-020-00235-0
Ahn S, Hwang SH, Han J, Choi YL, Lee SH, Ahn JS, et al. Transformation to Small Cell Lung Cancer of Pulmonary Adenocarcinoma: Clinicopathologic Analysis of Six Cases. J Pathol Transl Med. 2016;50(4):258-63. doi: https://doi.org/10.4132/jptm.2016.04.19
Khan P, Siddiqui JA, Maurya SK, Lakshmanan I, Jain M, Ganti AK, et al. Epigenetic landscape of small cell lung cancer: small image of a giant recalcitrant disease. Semin Cancer Biol. 2022;83:57-76. doi: https://doi.org/10.1016/j.semcancer.2020.11.006
Osman A, Afify SM, Hassan G, Fu X, Seno A, Seno M. Revisiting Cancer Stem Cells as the Origin of Cancer-Associated Cells in the Tumor Microenvironment: A Hypothetical View from the Potential of iPSCs. Cancers (Basel). 2020;12(4):879. doi: https://doi.org/10.3390/cancers12040879
Sainz de Aja J, Dost AFM, Kim CF. Alveolar progenitor cells and the origin of lung cancer. J Intern Med. 2021;289(5):629-35. doi: https://doi.org/10.1111/joim.13201
Shao Y, Zhong DS, Guan SS. Histologic transformation of lung adenocarcinoma to squamous cell carcinoma after chemotherapy: two case reports. Transl Cancer Res. 2020;9(1):388-93. doi: https://doi.org/10.21037/tcr.2019.11.34
Drapkin BJ, Rudin CM. Advances in Small-Cell Lung Cancer (SCLC) Translational Research. Cold Spring Harb Perspect Med. 2021;11(4):a038240. doi: https://doi.org/10.1101/cshperspect.a038240
Zakowski MF, Ladanyi M, Kris MG; Memorial Sloan-Kettering Cancer Center Lung Cancer OncoGenome Group. EGFR mutations in small-cell lung cancers in patients who have never smoked. N Engl J Med. 2006;355(2):213-5. doi: https://doi.org/10.1056/NEJMc053610
Ham JS, Kim S, Kim HK, Byeon S, Sun JM, Lee SH, et al. Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment. J Thorac Oncol. 2016;11(1):e1-4. doi: https://doi.org/10.1016/j.jtho.2015.09.013
Ahn S, Hwang SH, Han J, Choi YL, Lee SH, Ahn JS, et al. Transformation to Small Cell Lung Cancer of Pulmonary Adenocarcinoma: Clinicopathologic Analysis of Six Cases. J Pathol Transl Med. 2016;50(4):258-63. doi: https://doi.org/10.4132/jptm.2016.04.19
Wu PS, Lin MH, Hsiao JC, Lin PY, Pan SH, Chen YJ. EGFR-T790M Mutation-Derived Interactome Rerouted EGFR Translocation Contributing to Gefitinib Resistance in Non-Small Cell Lung Cancer. Mol Cell Proteomics. 2023;22(9):100624. doi: https://doi.org/10.1016/j.mcpro.2023.100624
Majem M, Sullivan I, Viteri S, López-Vivanco G, Cobo M, Sánchez JM, et al. First-line osimertinib in patients with epidermal growth factor receptor-mutant non-small-cell lung cancer and with a coexisting low allelic fraction of Thr790Met. Eur J Cancer. 2021;159:174-81. doi: https://doi.org/10.1016/j.ejca.2021.09.039
Hou X, Li M, Wu G, Feng W, Su J, Jiang H, et al. Gefitinib Plus Chemotherapy vs Gefitinib Alone in Untreated EGFR-Mutant Non-Small Cell Lung Cancer in Patients With Brain Metastases: The GAP BRAIN Open-Label, Randomized, Multicenter, Phase 3 Study. JAMA Netw Open. 2023;6(2):e2255050. doi: https://doi.org/10.1001/jamanetworkopen.2022.55050
Bai W, Zhen C, Zhang R, Yu W, Zhou Z. Clinicopathological features of patients with transformation from EGFR mutant lung adenocarcinoma to small cell lung cancer. Transl Cancer Res. 2021;10(8):3694-704. doi: https://doi.org/10.21037/tcr-21-653
Ahmed T, Vial MR, Ost D, Stewart J, Hasan MA, Grosu HB. Non-small cell lung cancer transdifferentiation into small cell lung cancer: A case series. Lung Cancer. 2018;122:220-3. doi: https://doi.org/10.1016/j.lungcan.2018.06.024
Sato Y, Saito G, Fujimoto D. Histologic transformation in lung cancer: when one door shuts, another opens. Ther Adv Med Oncol. 2022;14:17588359221130503. doi: https://doi.org/10.1177/17588359221130503
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeThe Effect of Open Access).
